Vertos Medical News This Article

Vertos Medical Announces ASC Reimbursement Increase for the mild® Procedure

Source— Vertos Medical December 8, 2020

ALISO VIEJO, Calif. — Vertos Medical Inc., a leader in the development of innovative, minimally invasive treatments for lumbar spinal stenosis (LSS), today announced that the Centers for Medicare and Medicaid Services (CMS) has increased Ambulatory Surgery Center (ASC) reimbursement for the mild® Procedure.

Effective January 1, 2021, the national average ASC reimbursement for CPT 0275T will increase by 41%, from $2,803.35 to $3,941.14, in recognition of the device cost associated with the procedure.

“The mild® Procedure is ideally suited for an ASC setting and we are pleased that CMS has improved the reimbursement for these facilities. We believe this will significantly increase patient access to the mild® Procedure across the country,” said Philip Macdonald, Vice President, Market Access & Reimbursement for Vertos Medical.

The mild® Procedure is a clinically proven outpatient LSS treatment that removes a major root cause of stenosis through a portal the size of a baby aspirin. It requires no implants, no general anesthesia, no stitches, no steroids or opioids and no overnight hospital stay.

The mild® Procedure is approved nationally for Medicare and Medicare Advantage patients and various regional private insurers. Coverage stands  at over 80 million lives. Since the FDA clearance in 2006, the mild® Procedure has been performed on more than 30,000 patients and its safety and efficacy have been analyzed in 13 clinical studies and over 25 publications.

© 2020 Vertos Medical, Inc. All Rights Reserved.